Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria.
Two studies comparing the cost-effectiveness of irbesartan to similar blood pressure control with standard antihypertensive medications (excluding angiotensin-converting enzyme inhibitors and other angiotensin receptor blockers) in treatment of patients with hypertension, type 2 diabetes, and microalbuminuria have been published to date; one in a United States setting, the other in a Spanish setting. Both studies were based on a Markov-based Monte Carlo simulation model, with the effects of irbesartan or standard blood pressure control taken from the Irbesartan Reduction of Microalbuminuria-2 (IRMA-2) and the Irbesartan in Diabetic Nephropathy Trial (IDNT) clinical trials. In both Spanish and U.S. settings, irbesartan was projected to delay the onset of end-stage renal disease (ESRD), reduce the cumulative incidence of ESRD, increase life expectancy, and reduce overall direct medical costs. Irbesartan treatment of patients with type 2 diabetes, hypertension, and microalbuminuria may lead to major improvements in long-term patient outcomes, with substantial cost savings as an added bonus to third party payers.
Center for Outcomes Research, Binningen/Basel, Switzerland. ap@thecenter.ch
Andrew J
AJ
Palmer
Roger A
RA
Rodby
D000419:Albuminuria / Q000188:drug therapy / Q000191:economics*; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000191:economics* / Q000627:therapeutic use; D017046:Cost Savings; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy / Q000191:economics*; D000077405:Irbesartan; D013777:Tetrazoles / Q000191:economics* / Q000627:therapeutic use
D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan